Stimulant-responsive and stimulant-refractory aggressive behavior among children with ADHD

Pediatrics

Volumn 126, Issue 4, 2010, Pages

  Blader, Joseph C ^a,b   Pliszka, Steven R ^c   Jensen, Peter S ^d,e   Schooler, Nina R ^b   Kafantaris, Vivian ^b  

^a STONY BROOK UNIVERSITY   (United States)

^b ZUCKER HILLSIDE HOSPITAL   (United States)

^c Mays Cancer Center at UT Health San Antonio   (United States)

^d MAYO CLINIC   (United States)

^e REsource for Advancing Children's Health   (United States)

Author keywords

Aggression; Attention deficit and disruptive behavior disorders; Clinical trial; Drug therapy

Indexed keywords

AMPHETAMINE; DEXAMPHETAMINE; METHYLPHENIDATE; CENTRAL STIMULANT AGENT; DELAYED RELEASE FORMULATION;

ABDOMINAL PAIN; ADOLESCENT; AGGRESSION; ANXIETY; APATHY; ARTICLE; ATTENTION DEFICIT DISORDER; BEHAVIOR THERAPY; CHILD; CLINICAL PROTOCOL; CLINICAL TRIAL; CONDUCT DISORDER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYING; DECREASED APPETITE; DEPRESSION; DIARRHEA; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG ERUPTION; DRUG INDUCED HEADACHE; ECCHYMOSIS; EMOTIONAL STRESS; ENERGY; ENURESIS; FAMILY THERAPY; FATIGUE; FEMALE; HABIT; HEART PALPITATION; HUMAN; HYPERACTIVITY; HYPOACTIVITY; INCREASED APPETITE; INSOMNIA; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MANIA; MODIFIED OVERT AGGRESSION SCALE; MONOTHERAPY; MORNING DOSAGE; NERVOUSNESS; NIGHTMARE; OPPOSITIONAL DEFIANT DISORDER; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; PSYCHOMOTOR DISORDER; PSYCHOSOCIAL CARE; REMISSION; RESTLESSNESS; SADNESS; SCHOOL CHILD; SEX DIFFERENCE; SIDE EFFECT; STIMULUS RESPONSE; STOMACH PAIN; TIC; TREMOR; WAKEFULNESS; XEROSTOMIA; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; COMPLICATION; DELAYED RELEASE FORMULATION; DRUG EFFECTS; TREATMENT FAILURE;

ADOLESCENT; AGGRESSION; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CONDUCT DISORDER; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; MALE; METHYLPHENIDATE; TREATMENT FAILURE;

EID: 77957710562     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2010-0086     Document Type: Article

References (35)

1. Brown RT, Amler RW, Freeman WS, et al. Treatment of attention-deficit/ hyperactivity disorder: overview of the evidence. Pediatrics. 2005;115(6). Available at: www. pediatrics.org/cgi/content/full/115/6/e749
2. Greenhill LL, Halperin JM, Abikoff H. Stimulant medications. J Am Acad Child Adolesc Psychiatry. 1999;38(5):503-512
3. Klein RG, Abikoff H, Klass E, Ganeles D, Seese LM, Pollack S. Clinical efficacy of methylphenidate in conduct disorder with and without attention deficit hyperactivity disorder. Arch Gen Psychiatry. 1997;54(12):1073-1080
4. Connor D, Glatt S, Lopez I, Jackson D, Melloni R. Psychopharmacology and aggression: I - a meta-analysis of stimulant effects on overt/covert aggression: related behaviors in ADHD. J Am Acad Child Adolesc Psychiatry. 2002;41(3):253-261
5. Olfson M, Blanco C, Liu L, Moreno C, Laje G. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry. 2006; 63(6):679-685 (Pubitemid 43848299)
6. Patel NC, Crismon ML, Hoagwood K, et al. Trends in the use of typical and atypical antipsychotics in children and adolescents. J Am Acad Child Adolesc Psychiatry. 2005; 44(6):548-556 (Pubitemid 40720954)
7. Crystal S, Olfson M, Huang C, Pincus H, Gerhard T. Broadened use of atypical antipsychotics: safety, effectiveness, and policy challenges. Health Aff (Millwood). 2009;28(5):w770-w781
8. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA. 2009; 302(16):1765-1773
9. Sikich L, Frazier JA, McClellan J, et al. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) Study. Am J Psychiatry. 2008; 165(11):1420-1431
10. Cheng-Shannon J, McGough JJ, Pataki C, McCracken JT. Second-generation antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol. 2004;14(3):372-394 (Pubitemid 39473123)
11. Pliszka SR, Crismon ML, Hughes CW, et al. The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/ hyperactivity disorder (ADHD). J Am Acad Child Adolesc Psychiatry. 2006;45(6): 642-657
12. Connor DF, Carlson GA, Chang KD, et al. Juvenile maladaptive aggression: a review of prevention, treatment, and service configuration and a proposed research agenda. J Clin Psychiatry. 2006;67(5):808-820
13. Jensen PS, Youngstrom EA, Steiner H, et al. Consensus report on impulsive aggression as a symptom across diagnostic categories in child psychiatry: implications for medication studies. J Am Acad Child Adolesc Psychiatry. 2007;46(3):309-322
14. Blader JC, Jensen PS. Aggression in children: an integrative approach. In: Martin A, Volkmar FR, eds. Lewis' Textbook of Child and Adolescent Psychiatry. 4th ed. Baltimore, MD: Lippincott Williams & Wilkins; 2007:467-483
15. Dubovsky SL. How to reduce mania risk when prescribing stimulants: evidence-based hierarchy helps when bipolar and ADHD symptoms overlap. Curr Psychiatry. 2005;4(10):36-54
16. Mick E, Spencer T, Wozniak J, Biederman J. Heterogeneity of irritability in attention-deficit/ hyperactivity disorder subjects with and without mood disorders. Biol Psychiatry. 2005;58(7):576-582 (Pubitemid 41457304)
17. Leibenluft E, Charney DS, Towbin KE, Bhangoo RK, Pine DS. Defining clinical phenotypes of juvenile mania. Am J Psychiatry. 2003;160(3):430-437 (Pubitemid 41094250)
18. Blader JC, Schooler NR, Jensen PS, Pliszka SR, Kafantaris V. Adjunctive divalproex sodium vs. placebo for children with ADHD and aggression refractory to stimulant monotherapy. Am J Psychiatry. 2009;166(12): 1392-1401
19. Newcorn JH, Sutton VK, Zhang S, et al. Characteristics of placebo responders in pediatric clinical trials of attention-deficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2009;48(12):1165-1172
20. Kaufman J, Birmaher B, Brent D, et al. Schedule for Affective Disorders and Schizophrenia for School-Age Children- Present and Lifetime Version (K-SADS-PL): initial reliability and validity. J Am Acad Child Adolesc Psychiatry. 1997;36(7): 980-988
21. Donovan SJ, Stewart JW, Nunes EV, et al. Divalproex treatment for youth with explosive temper and mood lability: a doubleblind, placebo-controlled crossover design. Am J Psychiatry. 2000;157(5):818-820
22. Conners CK. Conners' Rating Scales-Revised. Technical Manual. North Tonawanda, NY: Multi- Health Systems; 1997
23. Poznanski EO, Mokros HB. Children's Depression Rating Scale-Revised. Los Angeles, CA: Western Psychological Services; 1995
24. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133: 429-435
25. Barkley RA, McMurray MB, Edelbrock CS, Robbins K. Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systemic, placebo-controlled evaluation. Pediatrics. 1990;86(2):184-192 (Pubitemid 20238848)
26. Greenhill LL, Abikoff HB, Arnold LE, et al. Medication treatment strategies in the MTA study: Relevance to clinicians and researchers. J Am Acad Child Adolesc Psychiatry. 1996;35(10):1304-1313
27. Abikoff H, Hechtman L, Klein R, et al. Symptomatic improvement in children with ADHD treated with long-term methylphenidate and multimodal psychosocial treatment. J Am Acad Child Adolesc Psychiatry. 2004; 43(7):802-811 (Pubitemid 38808485)
28. MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 1999;56(12): 1073-1086
29. Cunningham CE, Bremner RB, Secord- Gilbert M. COPE: The Community Parent Education Program: A School Based Family Systems Oriented Workshop for Parents of Children With Disruptive Behavior Disorders. Hamilton, Ontario, Canada: COPE Works; 2000
30. Pelham WE, Gnagy EM, Burrows-Maclean L, et al. Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics. 2001;107(6). Available at: www. pediatrics.org/cgi/content/full/107/6/e105
31. Dunlap WP, Cortina JM, Vaslow JB, Burke MJ. Meta-analysis of experiments with matched groups or repeated measures designs. Psychol Methods. 1996;1(2):170-177
32. McNeil Pediatrics. Concerta® (Methylphenidate HCl) Extended-Release Tablets: Full Prescribing Information. Titusville, NJ: Mc- Neil Pediatrics; June 2009
33. Olfson M, Marcus S, Wan G. Stimulant dosing for children with ADHD: a medical claims analysis. J Am Acad Child Adolesc Psychiatry. 2009;48(1):51-59
34. American Academy of Pediatrics, Subcommittee on Attention-Deficit/ Hyperactivity Disorder and Committee on Quality Improvement. Clinical practice guideline: treatment of the school-aged child with attention-deficit/ hyperactivity disorder. Pediatrics. 2001;108(4):1033-1044
35. American Academy of Child and Adolescent Psychiatry Committee on Health Care Access and Economics, American Academy of Pediatrics Task Force on Mental Health. Improving mental health services in primary care: reducing administrative and financial barriers to access and collaboration [published correction appears in Pediatrics. 2009;123(6):1611. Pediatrics. 2009;123(4): 1248-1251